m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00082
 [1], [2]
m6A modification ADARB1 ADARB1 YTHDF2 : m6A sites Direct Inhibition RNA modification FLNA FLNA ADARB1 Methylation : modification sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Double-stranded RNA-specific editase 1 (ADARB1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Double-stranded RNA-specific editase 1 (ADARB1) WRITER View Details
Regulated Target Filamin-A (FLNA) View Details
Crosstalk Relationship m6A  →  A-to-I Inhibition
Crosstalk Mechanism m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary YTHDF2 recognizes the m6A methylation sites and prevents Double-stranded RNA-specific editase 1 (ADARB1) dependent A-to-I RNA editing of Filamin-A (FLNA).
Responsed Drug PTI-125
 Drug Info 
In-vitro Model
 A-172 Glioblastoma Homo sapiens CVCL_0131
HeLa Endocervical adenocarcinoma Homo sapiens CVCL_0030
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Filamin-A (FLNA) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PTI-125 Phase 2 [3]
Synonyms
UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46195331
TTD: D6ETD2
 Compound Name PTI-125 Phase 1 [4]
MOA Inhibitor
External Link
TTD: D0X2HJ
References
Ref 1 N6-methyladenosine promotes induction of ADAR1-mediated A-to-I RNA editing to suppress aberrant antiviral innate immune responses. PLoS Biol. 2021 Jul 29;19(7):e3001292. doi: 10.1371/journal.pbio.3001292. eCollection 2021 Jul.
Ref 2 Determination of editors at the novel A-to-I editing positions. Neurosci Res. 2008 Jun;61(2):201-6. doi: 10.1016/j.neures.2008.02.009. Epub 2008 Mar 13.
Ref 3 Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)